ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

Clinical Trial Information

Trial Contact: Jones, Jamie, Parker, Melanie, Armatti, Julie M, Singh, Sarah H, Frankos, Marie, Torrescano, Tanner

IRB No: S25.164.06

Principal Investigator: Rafique, Amina MD

Phase: N/A

Age Group: CHILDADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT04398628

Objective

To determine the safety of therapies used in the treatment of participants with congenital or acquired non-neoplastic blood disorders and connective tissue disorders with bleeding tendency. Safety will be measured by those events in the European Safety Surveillance (EUHASS). 1. Allergic or other acute events 2. Treatment-emergent side effects of therapy 3. Transfusion transmitted infections 4. Inhibitor development 5. Thrombosis 6. Cardiovascular events 7. Malignancies 8. Neurological events 9. Death

Share:

Related Clinical Trials

A Phase III Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in Subjects with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumors
An Interventional Open-Label Phase Ib/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in Combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
A Dose Escalation Study Using Difluoromethylornithine (DFMO) and AMXT-1501 followed by a Randomized Controlled Trial of DFMO with or without AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas
A Phase I/II Open-Label, Dose Escalation and Dose Optimization Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD8359, a CD8-Guided T Cell Engaging Antibody that Targets STEAP2, in Adult Participants with Prostate Cancer (CRIUS-1)